Therefore, the aim of this study was to evaluate the effectiveness of the intravenous form of mineralocorticoid receptor antagonist, potassium canrenoate, in the duration of invasive mechanical ventilation via endotracheal intubation or tracheotomy and duration of passive oxygen therapy in patients with COVID-19-associated pneumonia. This evidence concerns the gene NR3C2 and pneumonia.